The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Efficacy of Aromatase Inhibitors Combined with Growth Hormone Therapy in Male Adolescents with Idiopathic Short Stature

  • By

  • Yiling Cui

  • Qiting Zhang

  • Ling Hou

  • Xiaoping Luo

  • May 6, 2025

Share

Objective:

To evaluate the efficacy and safety of third-generation aromatase inhibitors combined with recombinant human growth hormone in male adolescents with idiopathic short stature and compare adult height augmentation with GnRH analog treatment as a control.

Key Findings:
  • The SD scores of adult height adjusted for target height were 0.60 ± 0.28 for letrozole, 0.81 ± 0.34 for anastrozole, and 0.48 ± 0.17 for GnRHa, with P < .01 for anastrozole vs. others.
  • Anastrozole combined with rhGH resulted in the most significant increase in adult height (P < .01) compared to letrozole and GnRHa.
  • Adverse events in the AIs group returned to normal after treatment cessation.
Interpretation:

The combination of aromatase inhibitors with rhGH significantly enhances adult height in male adolescents with ISS, with anastrozole showing superior efficacy and fewer adverse reactions, suggesting a promising alternative to GnRH analogs.

Limitations:
  • The study's sample size was limited to 96 participants, which may affect the generalizability of the results.
  • Long-term effects of AIs on growth and development in adolescents are not fully understood, and potential biases in sample selection and follow-up duration may exist.
Conclusion:

Aromatase inhibitors, particularly anastrozole, are effective in increasing adult height in male adolescents with idiopathic short stature and advanced bone age, providing a viable alternative to GnRH analogs.

Original Source(s)

The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents

  • by Yiling Cui, Qiting Zhang, Ling Hou, Xiaoping Luo

  • May 6, 2025

Related Content

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.